Review



plk1 rabbit polyclonal antibody  (Beyotime)


Bioz Verified Symbol Beyotime is a verified supplier
Bioz Manufacturer Symbol Beyotime manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Beyotime plk1 rabbit polyclonal antibody
    Plk1 Rabbit Polyclonal Antibody, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/anti+plk1/pm37844429-111-17-30
    Average 90 stars, based on 1 article reviews
    plk1 rabbit polyclonal antibody - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
    Article Snippet: Targeting the activated epidermal growth factor receptor (EGFR) via clustered regularly interspaced short palindromic repeat (CRISPR) technology is appealing to overcome the drug resistance of hepatocellular carcinoma (HCC) towards tyrosine kinase inhibitor (TKI) therapy.. However, combining these two distinct drugs using traditional liposomes results in a suboptimal synergistic anti-HCC effect due to the limited CRISPR/Cas9 delivery efficiency caused by lysosomal entrapment after endocytosis.. Herein, we developed a liver-targeting gene-hybridizing-TKI fusogenic liposome (LIGHTFUL) that can achieve high CRISPR/Cas9 expression to reverse the EGFR-mediated drug resistance for enhanced TKI-based HCC therapy efficiently.

    Western Blot:

    Article Title: A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy.
    Article Snippet: Targeting the activated epidermal growth factor receptor (EGFR) via clustered regularly interspaced short palindromic repeat (CRISPR) technology is appealing to overcome the drug resistance of hepatocellular carcinoma (HCC) towards tyrosine kinase inhibitor (TKI) therapy.. However, combining these two distinct drugs using traditional liposomes results in a suboptimal synergistic anti-HCC effect due to the limited CRISPR/Cas9 delivery efficiency caused by lysosomal entrapment after endocytosis.. Herein, we developed a liver-targeting gene-hybridizing-TKI fusogenic liposome (LIGHTFUL) that can achieve high CRISPR/Cas9 expression to reverse the EGFR-mediated drug resistance for enhanced TKI-based HCC therapy efficiently.



    Similar Products

    rabbit anti plk1  (Bioss)
    91
    Bioss rabbit anti plk1
    Rabbit Anti Plk1, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/PLK1+Polyclonal+Antibody/pm35810562-78-68-71
    Average 91 stars, based on 1 article reviews
    rabbit anti plk1 - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    anti-plk1 rabbit polyclonal antibody for crab proteins  (Sangon Biotech)
    90
    Sangon Biotech anti-plk1 rabbit polyclonal antibody for crab proteins
    Anti Plk1 Rabbit Polyclonal Antibody For Crab Proteins, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/sirna+plk1/pmc10968087-122-5-9
    Average 90 stars, based on 1 article reviews
    anti-plk1 rabbit polyclonal antibody for crab proteins - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    plk1 rabbit polyclonal antibody  (Beyotime)
    90
    Beyotime plk1 rabbit polyclonal antibody
    Plk1 Rabbit Polyclonal Antibody, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/anti+plk1/pm37844429-111-17-30
    Average 90 stars, based on 1 article reviews
    plk1 rabbit polyclonal antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti phospho plk1  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc rabbit polyclonal anti phospho plk1
    Rabbit Polyclonal Anti Phospho Plk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/Phospho-PLK1+(Thr210)+Antibody/pm37039032-405-7-11
    Average 95 stars, based on 1 article reviews
    rabbit polyclonal anti phospho plk1 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    anti phospho-plk1(t210) (rabbit polyclonal antibody, cat. 5472)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc anti phospho-plk1(t210) (rabbit polyclonal antibody, cat. 5472)
    Anti Phospho Plk1(t210) (Rabbit Polyclonal Antibody, Cat. 5472), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/anti+plk1/pm36894973-62-2-16
    Average 90 stars, based on 1 article reviews
    anti phospho-plk1(t210) (rabbit polyclonal antibody, cat. 5472) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rabbit anti-plk1 polyclonal antibody a2548  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology rabbit anti-plk1 polyclonal antibody a2548
    Correlation between <t>PLK1</t> gene expression and clinical parameters. (A) Box plot showing the differential expression of PLK 1 in TCGA-BRCA samples. (B) Kaplan-Meier curves showing OS of patients demarcated by PLK1 expression level in the TCGA-BRCA cohort. (C) ROC curves of 1-, 3-, and 5-year OS on the basis of PLK1 expression. Box plots showing the correlation of PLK1 expression with (D) age, (E) T stage, (F) pathological stage, (G) PR status, (H) ER status and (I) Her-2 status.
    Rabbit Anti Plk1 Polyclonal Antibody A2548, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/anti+plk4+antibody/pmc10765123-65-8-14
    Average 90 stars, based on 1 article reviews
    rabbit anti-plk1 polyclonal antibody a2548 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rabbit anti human plk1 polyclonal antibody  (Proteintech)
    94
    Proteintech rabbit anti human plk1 polyclonal antibody
    Correlation between <t>PLK1</t> gene expression and clinical parameters. (A) Box plot showing the differential expression of PLK 1 in TCGA-BRCA samples. (B) Kaplan-Meier curves showing OS of patients demarcated by PLK1 expression level in the TCGA-BRCA cohort. (C) ROC curves of 1-, 3-, and 5-year OS on the basis of PLK1 expression. Box plots showing the correlation of PLK1 expression with (D) age, (E) T stage, (F) pathological stage, (G) PR status, (H) ER status and (I) Her-2 status.
    Rabbit Anti Human Plk1 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plk1+rabbit+polyclonal+antibody/PLK1+Antibody/pm34738156-83-74-83
    Average 94 stars, based on 1 article reviews
    rabbit anti human plk1 polyclonal antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Correlation between PLK1 gene expression and clinical parameters. (A) Box plot showing the differential expression of PLK 1 in TCGA-BRCA samples. (B) Kaplan-Meier curves showing OS of patients demarcated by PLK1 expression level in the TCGA-BRCA cohort. (C) ROC curves of 1-, 3-, and 5-year OS on the basis of PLK1 expression. Box plots showing the correlation of PLK1 expression with (D) age, (E) T stage, (F) pathological stage, (G) PR status, (H) ER status and (I) Her-2 status.

    Journal: Oncology Research

    Article Title: Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients

    doi: 10.32604/or.2023.030887

    Figure Lengend Snippet: Correlation between PLK1 gene expression and clinical parameters. (A) Box plot showing the differential expression of PLK 1 in TCGA-BRCA samples. (B) Kaplan-Meier curves showing OS of patients demarcated by PLK1 expression level in the TCGA-BRCA cohort. (C) ROC curves of 1-, 3-, and 5-year OS on the basis of PLK1 expression. Box plots showing the correlation of PLK1 expression with (D) age, (E) T stage, (F) pathological stage, (G) PR status, (H) ER status and (I) Her-2 status.

    Article Snippet: After blocking, the membranes were incubated with a rabbit anti-PLK1 polyclonal antibody (A2548; Wuhan ABclonal Technology Co., Ltd., China), and then with a rabbit anti-goat secondary antibody (AS029).

    Techniques: Gene Expression, Quantitative Proteomics, Expressing

    Predictive ability of PLK1 in the TCGA-BRCA cohort. Results of the (A) univariate and (B) multivariate COX forest plots of PLK1 and clinical features.

    Journal: Oncology Research

    Article Title: Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients

    doi: 10.32604/or.2023.030887

    Figure Lengend Snippet: Predictive ability of PLK1 in the TCGA-BRCA cohort. Results of the (A) univariate and (B) multivariate COX forest plots of PLK1 and clinical features.

    Article Snippet: After blocking, the membranes were incubated with a rabbit anti-PLK1 polyclonal antibody (A2548; Wuhan ABclonal Technology Co., Ltd., China), and then with a rabbit anti-goat secondary antibody (AS029).

    Techniques:

    Validation of PLK1 mRNA and protein expression in BRCA. (A) PLK1 mRNA levels in the indicated cell lines. (B) PLK1 protein levels in the indicated cell lines. (C) IHC images from the Human Protein Atlas (HPA) database showing differential expression of PLK1 between the tumor and normal breast tissue samples. ** p < 0.01, and *** p < 0.001.

    Journal: Oncology Research

    Article Title: Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients

    doi: 10.32604/or.2023.030887

    Figure Lengend Snippet: Validation of PLK1 mRNA and protein expression in BRCA. (A) PLK1 mRNA levels in the indicated cell lines. (B) PLK1 protein levels in the indicated cell lines. (C) IHC images from the Human Protein Atlas (HPA) database showing differential expression of PLK1 between the tumor and normal breast tissue samples. ** p < 0.01, and *** p < 0.001.

    Article Snippet: After blocking, the membranes were incubated with a rabbit anti-PLK1 polyclonal antibody (A2548; Wuhan ABclonal Technology Co., Ltd., China), and then with a rabbit anti-goat secondary antibody (AS029).

    Techniques: Biomarker Discovery, Expressing, Quantitative Proteomics

    Association between immunotherapy response, immune-related scores and PLK1 expression in BRCA patients. (A) Box plot showing the correlation between PLK1 expression and pCR in the GSE173839 cohort. (B) Box plot showing the correlation between PLK1 expression and immunotherapy response. The IPS scores (C), TMB scores (D), MATH scores (E) and TIDE scores (F) in the PLK1-low and PLK1-high groups.

    Journal: Oncology Research

    Article Title: Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients

    doi: 10.32604/or.2023.030887

    Figure Lengend Snippet: Association between immunotherapy response, immune-related scores and PLK1 expression in BRCA patients. (A) Box plot showing the correlation between PLK1 expression and pCR in the GSE173839 cohort. (B) Box plot showing the correlation between PLK1 expression and immunotherapy response. The IPS scores (C), TMB scores (D), MATH scores (E) and TIDE scores (F) in the PLK1-low and PLK1-high groups.

    Article Snippet: After blocking, the membranes were incubated with a rabbit anti-PLK1 polyclonal antibody (A2548; Wuhan ABclonal Technology Co., Ltd., China), and then with a rabbit anti-goat secondary antibody (AS029).

    Techniques: Expressing

    Immune infiltration in the PLK1-high and PLK1-low groups.

    Journal: Oncology Research

    Article Title: Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients

    doi: 10.32604/or.2023.030887

    Figure Lengend Snippet: Immune infiltration in the PLK1-high and PLK1-low groups.

    Article Snippet: After blocking, the membranes were incubated with a rabbit anti-PLK1 polyclonal antibody (A2548; Wuhan ABclonal Technology Co., Ltd., China), and then with a rabbit anti-goat secondary antibody (AS029).

    Techniques:

    PLK1 expression can predict the benefits of immunotherapy. (A) Kaplan-Meier survival curves of PLK1-high and PLK1-low urothelial cancer patients in the lMvigor210 cohort. (B) Boxplot showing PLK1 expression in patients with different immunotherapy responses in the IMvigor210 cohort. CR: complete response, PR: partial response, and SD: stable disease, PD: partial response. (C) ROC curves showing the predictive ability of PLK1 for 1- and 2-year survival post-immunotherapy in the IMvigor210 cohort.

    Journal: Oncology Research

    Article Title: Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients

    doi: 10.32604/or.2023.030887

    Figure Lengend Snippet: PLK1 expression can predict the benefits of immunotherapy. (A) Kaplan-Meier survival curves of PLK1-high and PLK1-low urothelial cancer patients in the lMvigor210 cohort. (B) Boxplot showing PLK1 expression in patients with different immunotherapy responses in the IMvigor210 cohort. CR: complete response, PR: partial response, and SD: stable disease, PD: partial response. (C) ROC curves showing the predictive ability of PLK1 for 1- and 2-year survival post-immunotherapy in the IMvigor210 cohort.

    Article Snippet: After blocking, the membranes were incubated with a rabbit anti-PLK1 polyclonal antibody (A2548; Wuhan ABclonal Technology Co., Ltd., China), and then with a rabbit anti-goat secondary antibody (AS029).

    Techniques: Expressing